Novel postremission strategies in adults with acute myeloid leukemia

Current Opinion in Hematology

Volumn 16, Issue 2, 2009, Pages 105-111

  Lancet, Jeffrey E ^a   Karp, Judith E ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia; Leukemia stem cell; Minimal residual disease; Postremission therapy; Targeted therapy

Indexed keywords

BORTEZOMIB; CYTARABINE; HISTAMINE; MIDOSPAURIN; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; NUCLEOSIDE ANALOG; PARTHENOLIDE; PEPTIDE VACCINE; PROTEIN INHIBITOR; PROTEIN KINASE B INHIBITOR; TIPIFARNIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CELL POPULATION; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; REMISSION INDUCTION;

EID: 62249220561     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283257b04     Document Type: Review

References (63)

1. Appelbaum FR, Qundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107:3481-3485.
2. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006; 106:1090-1098.
3. Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 2004; 104: 1940-1951.
4. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89:3323-3329.
5. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999; 94:1086-1099.
6. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98:3212-3220.
7. Liu Yin JA, Wheatley K, Rees JKH, Burnett AK. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 2001; 113:713-726.
8. Solary E, Drenou B, Campos L, et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 2003; 102:1202-1210.
9. Advani R, Saba HI, Tallman MS, et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multi-drug resistance modulator PSC 833 (Valspodar). Blood 1999; 93:787-795.
10. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002; 100:1224-1232.
11. Cripe LD, Li X, Litzow M, et al. A randomized, placebo-controlled, double blind trial of the MDR modulator, Zosuquidar, during conventional induction and post-remission therapy for pts >60 years of age with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): ECOG 3999 [abstract no. 423]. ASH Annual Meeting Abstracts 2006:108.
12. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96:857-868.
13. Datta SR, Dudek H Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91:231-241.
14. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998; 10:262-267.
15. Kim AH, Khursigara G, Sun X, et al. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001; 21:893-901.
16. Grandage VL, Gale RE, Linen DC, Khwaja A. PI3-kinase//Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways. Leukemia 2005; 19:586-594.
17. Kubota Y, Ohnishi H, Kitanaka A, et al. Constitutive activation of P13K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of P13K activation. Leukemia 2004; 18:1438-1440.
18. Min YH, Eom JI, Cheong JW, et al. Constitutive phosphorylation of AkWPKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 2003; 17:995-997.
19. O'Gorman DM, McKenna SL, McGahon AJ, et al. Sensitization of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of P13-kinase survival signals. Leukemia 2000; 14:602-611.
20. Papa V, Tazzari PL, Chiarini F, et al. Proapoptotic activity and chemosensitiz ing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2007; 22:147-160.
21. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730-737.
22. Blair A, Hogge DE, Ailles LE, et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997; 89:3104-3112.
23. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003; 101:3142-3149.
24. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-{kappa}B is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98:2301-2307.
25. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005; 105:4163-4169.
26. Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007; 110:4427-4435. In the above study, an orally bioavailable analog of the naturally occurring compound parthenolide was found to be a very potent inducer of apoptosis in AML progenitor cells, leading to subsequent clinical development in phase 1 trials.
27. Bendall LJ, Daniel A, Kortlepel K, et al. Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells. Exp Hematol 1994; 22:1252-1260.
28. Bendall LJ, Makrynikola V, Hutchinson A, et al. Stem cell factor enhances the adhesion of AML cells to fibronectin and augments fibronectin-mediated antiapoptotic and proliferative signals. Leukemia 1998; 12:1375-1382.
29. Manabe A, Coustan-Smith E, Behm FG, et al. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 1992; 79:2370-2377.
30. Liesveld JL, Harbol AW, Abboud CN. Stem cell factor and stromal cell coculture prevent apoptosis in a subculture of the megakaryoblastic cell line, UT-7. Leuk Res 1996; 20:591-600.
31. Konopleva M, Konoplev S, Hu W, et al. Stromal cells prevent apoptosis of AML cells by up-regulation of antiapoptotic proteins. Leukemia 2008; 16:1713-1724.
32. Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemio-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003; 9:1158-1165.
33. Garrido SM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 2001; 29:448-457.
34. Shen W, Bendall LJ, Gottlieb DJ, Bradstock KF. The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp Hematol 2001; 29:1439-1447.
35. Tavor S, Petit I, Porozov S, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004; 64:2817-2824.
36. Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2008. http://bloodjournal.hematologylibrary.org/ cgi/ content/abstract/blood-2008-05-158311v1. [Epub ahead of print] It was shown in this article that disruption of SDF-1/CXCR4 interactions via CXCR4 inhibition enhances antileukemic effects of chemotherapy and a FLT-3 inhibitor.
37. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112:990-998.
38. Flomenberg N, Devine SM, DiPersio JF, et al. The use of AMD31OO plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106:1867-1874.
39. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85:1416-1434.
40. Kern W, Voskova D, Schoch C, et al. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multi-parameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104:3078-3085.
41. San Miguel JF, Martinez A, Macedo A, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90:2465-2470.
42. Venditti A, Buccisano F, Del Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96:3948-3952.
43. Buccisano F, Maurillo L, Gattei V, et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 2006; 20:1783-1789.
44. Kern W, Voskova D, Schoch C, et al. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. Haematologica 2004; 89:528-540.
45. Laane E, Derolf AR, Bjorklund E, et al. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of postremission chemotherapy. Haematologica 2006; 91:833-836.
46. Mrozek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007; 109:431-448.
47. Burnett AK, Grimwade D, Solomon E, et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999; 93:4131-4143.
48. Diverio D, Rossi V, Avvisati G, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RAR-alpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter 'AIDA' trial. Blood 1998; 92:784-789.
49. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid-leukemia. N Engl J Med 1994; 331:896-903.
50. Paulas C, Thomas X, Merabet F, et al. Randomized comparison of standard induction with daunorubicin (DNR) for 3 days vs idarubicin (IDA) for 3 or 4 days in AML pts aged 50 to 70 and of maintenance with interleukin 2, Final analysis of the ALFA 9801 Study [abstract no. 162]. ASH Annual Meeting Abstracts 2007; 110.
51. Kantarjian H, Issa JP, Rosenfeld CS, et al, Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study [see comment]. Cancer 2006; 106:1794-1803.
52. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a Study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20:2429-2440.
53. Silverman LR, McKenzie DR, Peterson BL, et al. Response rates in patients with acute myeloid leukemia (AML), treated with azacitidine, using WHO and International Working Group (IWG) criteria for myelodysplastic syndrome (MDS) [abstract no. 1848], ASH Annual Meeting Abstracts 2005: 106. 54 Lubbert M, Ruter B, Claus R, et al. Continued low-dose decitabine (DAC) is an active first-line treatment in all cytogenetic subgroups of older AML patients: results of the FR00331 multicenter phase Il study [abstract no. 300], ASH Annual Meeting Abstracts 2007: 110.
54. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxy- cytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635-1640.
55. Grovdal M, Khan R, Aggerholm A, et al. Maintenance treatment with azac• tidine for patients with high risk myelodysplastic syndromes or acute myeloid leukaemia in complete remission after intensive chemotherapy [abstract no. 818]. ASH Annual Meeting Abstracts 2007: 110. Preliminary results of a trial utilizing 5-azacitidine maintenance therapy for older patients with AML in the first complete remission following chemotherapy, sug-gesting ability to obtain durable complete remissions in some patients .
56. Karp JE, Smith BD, Gojo I, et al. Phase Il trial of tipifarnib as maintenance • therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res 2008; 14:3077-3082. A phase 2 trial of poor-risk patients with AML in CR1, who were treated with tipifarnib (a FTI) as maintenance therapy. There was a signal of prolonged DFS compared with historic controls .
57. Brune M, Castaigne S, Catalano J, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006; 108:88-96.
58. Kolitz JE, Hars V, DeAngelo DJ, et al. Phase III trial of immunotherapy with recombinant interleukin-2 (rlL-2) versus observation in patients <60 years with acute myeloid leukemia (AML) in first remission (CR1) : preliminary results from Cancer and Leukemia Group B (CALGB) 19808 [abstract no. 157]. ASH Annual Meeting Abstracts 2007: 110.
59. Dengler R, Muunstermann U, Al-Batran S, et al. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemia myeloid cells. Br J Haematol 1995; 89:250-257.
60. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89:1405-1412.
61. Molldrem J, Dermime S, Parker K, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88:2450-2457.
62. Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100:2132-2137.
63. Qazilbash MH, Wieder ED, Thall PF, et al. PR1 peptide vaccine-induced immune response is associated with better event-free survival in patients with myeloid leukemia [abstract no. 283]. ASH Annual Meeting Abstracts 2007: 110. A recent article demonstrating a peptide vaccine-induced T-cell immune response in AML, along with evidence of clinical responses.